Outcome of Transforminal Epidural Injections in Patients with Lumbar Radicular Pain

NCT ID: NCT06656429

Last Updated: 2024-10-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 62 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-10-01
• Study Completion Date: 2022-09-30

Brief Summary

Back pain is the most common chronic pain disorder of adult population. Lumbar radicular pain occurs due to irritation or compression of the nerve roots in the lower back. Various non-surgical methods can also be exercised that have been used to treat lumbar radicular pain since the ancient times. Despite the availability of various treatment options, achieving optimal pain relief and functional recovery remains challenging. Lumbar Transforaminal Epidural Steroid Injections (TFESI) are commonly used to manage this condition, but there is variability in patient response and limited data on the effectiveness of TFESI in different demographic and clinical subgroups.

Conditions

Lumbar Redicular Pain

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

TFESI

Lumbar Transforaminal Epidural Steroid Injections was administered, consisting of 4 mg dexamethasone and 0.33% lidocaine in a 3 ml solution.

Group Type: EXPERIMENTAL

Transforaminal Epidural Steroid Injections

Intervention Type: DRUG

Transforaminal Epidural Steroid Injections

Interventions

Transforaminal Epidural Steroid Injections

Transforaminal Epidural Steroid Injections

Intervention Type: DRUG

Other Intervention Names

Lumbar transforaminal epidural steroid Injection was administered, consisting of 4 mg dexamethasone and 0.33% lidocaine in a 3 ml solution

Eligibility Criteria

Inclusion Criteria

• Both genders
• Aged between 45 and 80 years
• Experiencing lumbar radicular pain

Exclusion Criteria

• History of spinal fracture or previous spinal surgery
• Recurrent pain within 3 months of prior treatment
• Ongoing steroid therapy
• IKnown allergy to dexamethasone or lidocaine

• Minimum Eligible Age: 45 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Muhammad Aamir Latif

OTHER

Sponsor Role: lead

Responsible Party

Muhammad Aamir Latif

Consultant

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Muhammad Zarak Awais, MBBS

Role: PRINCIPAL_INVESTIGATOR

Department of Orthopedic Surgery, Mayo Hospital, Lahore, Pakistan

Locations

Mayo Hospital

Lahore, Punjab Province, Pakistan

Countries

Pakistan

Other Identifiers

Mayo-1

Identifier Type: -

Identifier Source: org_study_id